Quick Answer
CRESCENT BIOPHARMA, INC. reported Research And Development Expense of $138.09 million for the year ending 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +868.4% in Research And Development Expense from 2024 to 2025.
- This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $2.74 million | Q2 2013: $2.88 million | Q3 2013: $2.95 million | Q1 2014: $3.88 million | Q2 2014: $5.36 million | Q3 2014: $5.05 million | Q1 2015: $5.21 million | Q2 2015: $7.84 million | Q3 2015: $5.04 million | Q1 2016: $5.52 million | Q2 2016: $5.78 million | Q3 2016: $5.92 million | Q1 2017: $5.88 million | Q2 2017: $5.72 million | Q3 2017: $5.78 million | Q1 2018: $9.30 million | Q2 2018: $9.30 million | Q3 2018: $9.73 million | Q1 2019: $11.77 million | Q2 2019: $13.07 million | Q3 2019: $10.72 million | Q1 2020: $12.67 million | Q2 2020: $9.87 million | Q3 2020: $10.67 million | Q1 2021: $11.15 million | Q2 2021: $10.17 million | Q3 2021: $13.28 million | Q1 2022: $9.60 million | Q2 2022: $7.97 million | Q3 2022: $4.92 million | Q1 2023: $5.42 million | Q2 2023: $4.07 million | Q3 2023: $5.29 million | Q1 2024: $6.03 million | Q2 2024: $6.29 million | Q3 2024: $1.72 million | Q3 2024: $2.47 million | Q4 2024: $14.03 million | Q1 2025: $14.8 thousand | Q2 2025: $12.08 million | Q3 2025: $20.35 million.
- Over the full 14 years of available data (2012 to 2025), CRESCENT BIOPHARMA, INC.'s Research And Development Expense has grown by 1,363.0%.
- Historical annual values: Fiscal year 2025: $138.09 million | Fiscal year 2024: $14.26 million | Fiscal year 2023: $20.07 million | Fiscal year 2022: $28.39 million | Fiscal year 2021: $47.49 million | Fiscal year 2020: $44.93 million | Fiscal year 2019: $47.03 million | Fiscal year 2018: $40.09 million | Fiscal year 2017: $24.10 million | Fiscal year 2016: $23.28 million | Fiscal year 2015: $25.05 million | Fiscal year 2014: $19.57 million | Fiscal year 2013: $11.70 million | Fiscal year 2012: $9.44 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: